Date: 2018-01-03
Type of information: Collaboration agreement
Compound:
- EpiSwitch™ technology for use in the development of new predictive biomarkers for immuno-oncology therapies
- EpiSwitch™ technology for use in the analysis of structure-function of genome architecture and new insights into fibrotic mechanisms, new targets and new biomarkers
Company: Oxford BioDynamics (UK) undisclosed major US biopharmaceutical company
Therapeutic area: Cancer - Oncology - Fibrotic diseases
Type agreement: collaboration - development
Action mechanism: biomarker/companion diagnostic
Disease:
Details:
- • On January 3, 2018, Oxford BioDynamics (OBD) has signed a second collaboration agreement with major US biopharmaceutical company to extend its development of predictive biomarkers for immuno-oncology (IO) therapies. The first collaboration with this company was announced on 7 November 2017.
- Under the terms of the collaboration agreement, the US biopharmaceutical company will be granted access
to OBD’s unique EpiSwitch™ technology for use in the development of new predictive biomarkers for IO
therapies. This will support the development of next-generation companion diagnostics, and enable patient
population stratification for clinical trials in the IO field.
To date, OBD has entered into four agreements to discover and develop predictive biomarkers for IO therapeutics, two with pharmaceutical companies, one with a major US healthcare concern and the latest agreement with a major US biopharmaceutical company.
- • On November 7, 2017, Oxford BioDynamics announced that it has entered into an initial collaboration with a major US biopharmaceutical company to advance the discovery and development of novel treatments to address patients with abnormal wound healing response, leading to fibrosis. Under the terms of the collaboration agreement, the US partner will be granted access to OBD’s unique EpiSwitch™ technology for use in the analysis of structure-function of genome architecture and new insights into fibrotic mechanisms, new targets and new biomarkers. This will support the development of novel therapeutic candidates and next-generation companion diagnostics, and enable patient population stratification for clinical trials in the area of fibrosis.
Financial terms:
Latest news:
Is general: Yes